Floatz logo

ELAMIPRETIDE TRIHYDROCHLORIDE

Barth Syndrome

Stealth BioTherapeutics Inc.protein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Barth Syndrome cohort.

Asset / SponsorPhaseRating
HEPTANOIN, TRI-
D

Same molecule, other indications

ELAMIPRETIDE TRIHYDROCHLORIDE is also rated in:

Friedreich ataxiaDormant
CCC
Indicative ·
50 / 100
View asset →
mitochondrial diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →